Overcoming Obstacles in the Development of Antigen-Specific Immunotherapies for Type 1 Diabetes.
T1D
autoimmunity
immunotherapy
precision medicine
tolerance
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
06
2021
accepted:
22
07
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
24
12
2021
Statut:
epublish
Résumé
Antigen-specific immunotherapy (ASI) holds great promise for type 1 diabetes (T1D). Preclinical success for this approach has been demonstrated
Identifiants
pubmed: 34421931
doi: 10.3389/fimmu.2021.730414
pmc: PMC8375663
doi:
Substances chimiques
Antigens
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
730414Informations de copyright
Copyright © 2021 Thomas, Carballido, Wesley and Ahmed.
Déclaration de conflit d'intérêts
JC is an employee of Novartis. JW is an employee of Novo Nordisk. RT has filed provisional patents surrounding technology and is commercializing immunotherapy for targeting DCs for antigen-specific tolerance. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Diabetes. 2015 Jan;64(1):172-82
pubmed: 25157096
Front Med (Lausanne). 2018 Oct 09;5:283
pubmed: 30356664
Gastroenterology. 2021 Jul;161(1):66-80.e8
pubmed: 33722583
Clin Transl Immunology. 2021 Jul 26;10(7):e1315
pubmed: 34336205
Diabetes. 2010 Nov;59(11):2846-53
pubmed: 20699420
JCI Insight. 2021 Jan 25;6(2):
pubmed: 33301420
J Clin Invest. 2020 Jan 2;130(1):480-490
pubmed: 31815738
Neurology. 2018 Mar 13;90(11):e955-e962
pubmed: 29467307
Nat Rev Endocrinol. 2021 Mar;17(3):150-161
pubmed: 33293704
JCI Insight. 2021 Feb 8;6(3):
pubmed: 33351781
Diabetes Care. 2020 Jan;43(1):5-12
pubmed: 31753960
Diabetes. 2015 Mar;64(3):916-925
pubmed: 25249579
ACS Cent Sci. 2021 Apr 28;7(4):512-533
pubmed: 34056083
Diabetologia. 2016 Jun;59(6):1177-85
pubmed: 26796634
JAMA. 2013 Jun 19;309(23):2473-9
pubmed: 23780460
Curr Diab Rep. 2020 Nov 9;20(12):70
pubmed: 33169191
Lancet Diabetes Endocrinol. 2019 Jan;7(1):65-74
pubmed: 30528100
J Clin Invest. 2018 Aug 1;128(8):3460-3474
pubmed: 29851415
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007781
pubmed: 22474615
Neurol Neuroimmunol Neuroinflamm. 2015 Mar 12;2(3):e93
pubmed: 25798453
Diabetes. 2021 Apr;70(4):831-841
pubmed: 33741606
Nat Med. 2021 Jan;27(1):125-135
pubmed: 33432170
Front Immunol. 2020 Dec 07;11:587469
pubmed: 33424839
J Exp Med. 2019 Feb 4;216(2):247-250
pubmed: 30651299
Sci Transl Med. 2017 Aug 9;9(402):
pubmed: 28794283
Diabetes. 2019 Jul;68(7):1366-1379
pubmed: 31221801
Nat Biotechnol. 2019 Mar;37(3):238-251
pubmed: 30804535
Diabetes Care. 2021 May 21;:
pubmed: 34021020
Sci Immunol. 2016 Nov;1(5):
pubmed: 28664195
Diabetologia. 2019 Apr;62(4):567-577
pubmed: 30767048
Diabetes Care. 2015 Oct;38(10):1964-74
pubmed: 26404926
Sci Transl Med. 2017 Feb 22;9(378):
pubmed: 28228602